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Objectives: The aim of this study was to establish baseline, pre-progression and 
post-progression health state utilities for nivolumab (NIVO) and dacarbazine (DTIC) 
for use in the economic evaluation of NIVO versus other interventions in unresect-
able stage 3 or stage 4 melanoma. MethOds: Utility data were collected during a 
phase III clinical trial study every 6 weeks via the EQ-5D-3L instrument and ques-
tionnaires scored using Australian specific weights within Microsoft Excel. Utility 
valuations and associated patient and disease data were exported to STATA 11.2. 
Descriptive statistics were generated, stratified by treatment, study epoch (screen-
ing; non-screening) and by progressive disease status. Results: Two hundred and 
one and 208 patients were randomized to NIVO and DTIC respectively. Mean utili-
ties for NIVO and DTIC respectively were: 0.78 (95% CI: 0.75,0.81) and 0.71 (95% CI: 
0.67,0.75) at baseline; 0.84 (95% CI: 0.83,0.85) and 0.78 (95% CI: 0.76,0.81) prior to 
the development of progressive disease; and 0.83 (95% CI: 0.80,0.86) and 0.70 (95% 
CI: 0.66,0.74) following development of progressive disease. For those randomised 
to NIVO, development of progressive disease per RECIST v1.1 criteria did not sig-
nificantly impact on utility (mean change= 0.01, p= 0.4618). By contrast, for those 
randomised to DTIC, development of progressive disease per RECIST v1.1 criteria did 
significantly impact utility (mean change= 0.08, p= 0.0005). cOnclusiOns: These 
results provide Australian specific utility valuations by health state to inform the 
economic evaluation of NIVO versus other interventions in unresectable stage 3 or 
stage 4 melanoma. Notably, for those receiving NIVO, the development of progressive 
disease per RECIST v1.1 criteria did not have a significant impact on mean utility, 
suggesting the benefits of NIVO on HRQoL persist beyond traditional measures of 
disease progression, in contrast to DTIC which exhibits the expected reduction in 
utility following development of progressive disease
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Objectives: The standardized incidence of women breast cancer (BC) in Slovakia 
is 51,6/100 000 and has growing trend. There were diagnosed 2423 new cases in 2012 
and 2639 new cases BC in Slovakia. BC has a great impact on quality of life (QoL). 
The objective of this paper was to find out the level of QoL in patients with BC in 
Slovakia. MethOds: The primary method used for the analysis of QoL was the 
combined questionnaire consisting of 5 parts: A. Demography (9 items), B. Clinical 
part (B1+B2, 17 items), C. Quality fo life with dominant numeric scale (13 items), D. 
Socio-economic part (9 items), E. EQ-5D. There were 112 patients in the examined 
group from the 150 asked to fill the questionnaire. Results: Present level of QoL 
was identified as 6,11 on the scale from 0 to 10, while in the time of the BC diagnosis 
it was 4,42. QoL was 8.22 in the time without BC and 8,73 in the total optimal state 
of health. Comparative to the QoL was examined the ability to work (AW) and so on 
the scale from 0 to 10. Present level of AW was identified as 5,40, while in the time of 
the BC diagnosis it was 4,44. AW was 8.41 in the time without BC and 9,00 in the total 
optimal state of health. The impact of treatment on QoL was 5,38 and the disease 
had impact 6,10 on family QoL. Disability was 77,35 days vs 16,45 opposite to disabili-
ties days from other reasons. The average income was 379,58 € and the willingness 
to pay for 1 month of full health was in average 132 € per months. cOnclusiOns: 
The disease had a significant impact on patients´s QoL . The treatment of BC had a 
significant impact on increasing QoL of patients.
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Objectives: The standardized incidence of kidney cancer (KC) in Slovakia was 
14,6/100 000 in men and 7,0/100 000 in women and has growing trend. There were 
diagnosed more than 800 new cases in 2013 of KC in Slovakia. The objective of this 
paper was to find out the level of QoL in patients with KC in Slovakia. MethOds: 
The primary method used for the analysis of QoL was the combined questionnaire 
consisting of 6 parts: A. Demography (9 items), B. Clinical part (B1+B2, 17 items), C. 
Quality fo life with dominant numeric scale (13 items), D. Socio-economic part (9 
items), E. EQ-5D (5 items), F. Symptoms of disease (9 items). There were 79 patients 
in the examined group from the110 asked to fill the questionnaire. All patients 
were treated by surgery. Results: Present level of QoL was identified as 6,32 on the 
scale from 0 to 10 (0- the worst,10 -thebest), while in the time of the KC diagnosis it 
was 5,15. QoL was 7,86 in the time without BC and 8,82 in the total optimal state of 
health. Comparative to the QoL was examined the ability to work (AW), too. Present 
level of AW was identified as 6,02, while in the time of the BC diagnosis it was 5,44. 
AW was 8.25 in the time without KC and 9,06 in the total optimal state of health. 
The impact of treatment on QoL was 6,34 and the disease had impact 5,94 on family 
QoL. The average income was 456 € and the willingness to pay for 1 month was in 
average 270 € per months to be complete healthy. cOnclusiOns: The disease had 
a significant impact on patients´s QoL nad patient´s family QoL, too. The treatment 
of BC had a significant impact on increasing QoL of patients.
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Objectives: Willingness-to-pay techniques are increasingly being applied in eco-
nomic evaluation, as a means of assessing the value of new health care technologies. 
The objective of the present study was to assess the willingness to pay for Human 
Papillomavirus vaccination and factors influencing the willingness to pay among 
health professional students as health professionals play a vital role in human pap-
invasive BC (MIBC), which is invasive and requires lifetime urinary diversion, was most 
commonly studied. In contrast, there is minimal literature on HRQoL of patients with 
advanced/metastatic urothelial BC and non-muscle invasive BC (NMIBC). Although 
longitudinal studies have been conducted in both MIBC and NMIBC, the interpretation 
of the results is hampered by study design issues (such as lack of baseline HRQoL data, 
insufficient follow-up duration, infrequent HRQoL assessment, and/or small sample 
sizes) and inconsistency in HRQoL instrument. cOnclusiOns: While there is a sub-
stantial body of literature describing the impact of BC on HRQoL, particularly MIBC, 
methodological rigor is lacking, limiting interpretation and full assessment of the 
impact of BC by disease stage and treatment. Further, HRQoL assessment in NMIBC 
and advanced/metastatic disease is rare and warrants additional research effort.
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Objectives: As new interventions and treatment decision aids for prostate cancer 
(PC) become available, health economic analyses will be required to evaluate their 
impact on health authorities and the burden of PC. An important aspect of this is 
understanding the quality of life (QoL) impact of PC, its comorbidities and treat-
ments. MethOds: A structured literature review was undertaken, with searches 
conducted in PubMed, EMBASE, and the Cochrane Library. Literature review was con-
centrated on publications with a major focus on “Prostatic Neoplasms” or containing 
the term “Prostate Cancer”. Secondary search criteria restricted results to contain 
information on quality of life, health state utilities, or recognized QOL question-
naires. To ensure that recent estimates were evaluated, literature was restricted to 
those published on or after January 1, 2009. Abstract screening was performed by a 
single reviewer, with included results checked for alignment with the protocol by 
two further reviewers. Results: The mean QOL as measured using the EuroQOL 
5-dimension questionnaire (EQ-5D) was reported to be 0.86 for PC. After diagnosis of 
PC, a 0.02 point drop in the mean EQ-5D score was reported in the first two months 
of treatment. QOL assessment tools used, however, varied considerably between 
studies impairing data synthesis and comparison. Adverse events were commonly 
associated with PC treatments and resulted in decreased patient QOL. Urinary and 
sexual function problems were of greatest importance to males undergoing treat-
ment for PC. Erectile dysfunction was commonly reported and was present in 93.9% 
of men who received prostatectomy and radiotherapy. Nearly 14% of patients were 
willing to trade survival time for increased QOL. cOnclusiOns: PC is associated 
with reduced patient QOL and a large determinant in the QOL decrement appears to 
be the PC treatment received and its associated adverse events. Patient willingness 
to trade survival and QOL has important health economic implications.
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Objectives: In the PREVAIL trial, enzalutamide improved survival and HRQOL 
in men with chemo-naïve mCRPC. This analysis provides additional in-depth 
insights into the effects of enzalutamide and placebo on EQ-5D dimensions in 
PREVAIL. MethOds: In PREVAIL, the EQ-5D self-report questionnaire and Visual 
Analogue Scale (VAS) were used to assess HRQOL and were reported up to study 
week 61. Dimensions of health states were used to generate a summary score (EQ-5D 
Index) based upon UK societal preference weights. Paretian Classification of Health 
Change (PCHC) and time to event analyses were also conducted. Results: HRQOL 
deterioration (indicated by decreases in EQ-5D Index and VAS scores) was more 
gradual with enzalutamide versus placebo; reductions were significantly (p< 0.05) 
smaller with enzalutamide in EQ-5D Index up to Week 37 and in EQ-VAS up to Week 
61 (except Week 49). Benefits of enzalutamide were primarily in the Pain/Discomfort 
dimension, with significant between-group differences (p< 0.05) through to Week 
37. PCHC analysis showed a higher percentage of enzalutamide patients reporting 
improvements on EQ-5D dimensions up to Week 49 and a higher proportion of 
placebo patients reporting worsening up to week 25. Time to event analysis showed 
superiority of enzalutamide on time to shift from full health (state 11111) and time 
to first worsening on the Pain/Discomfort and Anxiety/Depression dimensions. At 
Week 61, of patients originally randomised to enzalutamide, 20.1% reported being 
in full health (state 11111), 28.2% reported no pain or discomfort, and 43.1% reported 
no anxiety/depression compared with 5.1%, 6.5%, and 10.2%, respectively, of placebo 
patients. cOnclusiOns: In PREVAIL, as well as improving overall survival versus 
placebo, enzalutamide showed HRQOL benefits captured through EQ-5D Index and 
VAS scores, including benefits in the Pain and Discomfort dimension of EQ-5D, and 
reporting being in full health, having no pain/discomfort, or no anxiety/depression.
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